Evidence map›Paper›PMID 25963221›Full record

Trial reportThe American journal of cardiology2015

Relation of frailty to outcomes after transcatheter aortic valve replacement (from the PARTNER trial).

Philip Green, Suzanne V Arnold, David J Cohen, Ajay J Kirtane, Susheel K Kodali, David L Brown, Charanjit S Rihal, Ke Xu, Yang Lei, Marian C Hawkey and 4 more

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The American journal of cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Philip GreenHerbert and Sandi Feinberg Interventional Cardiology and Heart Valve Center at Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York; Cardiovascular Research Foundation, New York, New York. Electronic address: pg2336@columbia.edu.
Suzanne V ArnoldSaint Luke's Mid America Heart Institute, Kansas City, Missouri.
David J CohenSaint Luke's Mid America Heart Institute, Kansas City, Missouri.
Ajay J KirtaneHerbert and Sandi Feinberg Interventional Cardiology and Heart Valve Center at Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York; Cardiovascular Research Foundation, New York, New York.
Susheel K KodaliHerbert and Sandi Feinberg Interventional Cardiology and Heart Valve Center at Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York; Cardiovascular Research Foundation, New York, New York.
David L BrownBaylor Healthcare System, Plano, Texas.
Charanjit S RihalMayo Clinic, Rochester, Minnesota.
Ke XuHerbert and Sandi Feinberg Interventional Cardiology and Heart Valve Center at Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York; Cardiovascular Research Foundation, New York, New York.
Yang LeiSaint Luke's Mid America Heart Institute, Kansas City, Missouri.
Marian C HawkeyHerbert and Sandi Feinberg Interventional Cardiology and Heart Valve Center at Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York; Cardiovascular Research Foundation, New York, New York.
Rebeca J KimCardiopulmonary Research Science and Technology Institute (CRSTI), Plano, Texas.
Maria C AluHerbert and Sandi Feinberg Interventional Cardiology and Heart Valve Center at Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York; Cardiovascular Research Foundation, New York, New York.
Martin B LeonHerbert and Sandi Feinberg Interventional Cardiology and Heart Valve Center at Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York; Cardiovascular Research Foundation, New York, New York.
Michael J MackCardiopulmonary Research Science and Technology Institute (CRSTI), Plano, Texas; Baylor Scott and White Health, Plano, Texas.

Funding

Optimal Decision Making in Aortic Valve ReplacementK23HL116799 · NHLBI · SAINT LUKE'S HOSPITAL · PI ARNOLD, SUZANNE VICTORIA · 2014 to 2018
$635k
Frailty related risk: Poor physiologic reserve during and after valve replacementK23HL121142 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GREEN, PHILIP · 2014 to 2016
$359k
NHLBI NIH HHS K23 HL116799NHLBI NIH HHS K23 HL12114NHLBI NIH HHS K23 HL121142
6 · The paper itself

Abstract

Transcatheter aortic valve replacement (TAVR) is an effective treatment for severe symptomatic aortic stenosis (AS) in patients who are inoperable or at high risk for surgery. However, the intermediate- to long-term mortality is high, emphasizing the importance of patient selection. We, therefore, sought to evaluate the prognostic value of frailty in older recipients of TAVR, hypothesizing that frail patients would experience a higher mortality rate and a higher likelihood of poor outcome 1 year after TAVR. This substudy of the Placement of Aortic Transcatheter Valves trial was conducted at 3 high-enrolling sites where frailty was assessed systematically before TAVR. In total, 244 patients received TAVR at the participating sites. Frailty was assessed using a composite of 4 markers (serum albumin, dominant handgrip strength, gait speed, and Katz activity of daily living survey), which were combined into a frailty score. The cohort was dichotomized at median frailty score. Outcomes measures were the time to death from any cause for >1 year of follow-up and poor outcome at 1 year. Poor outcome was defined as (1) death, (2) Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ-OS) score <60, or (3) decrease of ≥10 points in the KCCQ-OS score from baseline to 1 year. At 1 year, the Kaplan-Meier-estimated all-cause mortality rate was 32.7% in the frail group and 15.9% in the nonfrail group (log-rank p = 0.004). At 1 year, poor outcome occurred in 50.0% of the frail group and 31.5% of the nonfrail group (p = 0.02). In conclusion, frailty was associated with increased mortality and a higher rate of poor outcome 1 year after TAVR.

Indexed as

Frail ElderlyTranscatheter Aortic Valve ReplacementAgedAortic Valve StenosisFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMalePrognosisQuality of LifeSurveys and QuestionnairesSurvival RateTreatment OutcomeUnited States

Identifiers

PMID25963221
PMCPMC4475494

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.